U.S. President Donald Trump announced plans to impose tariffs on imported computer chips, pharmaceuticals, and steel, aiming to drive more manufacturing within the United States ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...
What about pharma? Imposing tariffs on imported pharmaceuticals could weigh on Japan, home of major drugmakers such as Takeda ...
Hosted on MSN11d
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks RetailBiogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...
Japanese drugmaker Eisai Co. Ltd. said on Monday it had submitted a marketing authorization application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated ...
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback